Related Experiment Video
Updated: Feb 28, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Focused Ultrasound in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Clinical
Olivia Sears1, Hongji Zhang1, Natalie Blatz1
1Department of Surgery, University of Virginia, Charlottesville, VA 22904, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy due to late presentation, limited resectability, therapeutic resistance, and a dense desmoplastic immunosuppressive tumor microenvironment that impairs drug penetration and antitumor immunity. Focused ultrasound (FUS) is an emerging non-invasive, image-guided therapeutic platform capable of delivering spatially confined acoustic energy to induce tumor ablation, disrupt stromal barriers, and enhance delivery of drugs, nanoparticles, and nucleic acids. Depending on acoustic parameters, FUS can produce thermal effects resulting in coagulative necrosis or non-thermal mechanical effects, including cavitation, sonoporation, and histotripsy which remodel extracellular matrix architecture, increase vascular and cellular permeability, and facilitate tumor debulking. In addition, FUS-induced cell injury can promote immunogenic cell death and release tumor-associated antigens and danger signals, providing a rationale for combination strategies with chemotherapy, radiation, and immunotherapy. This review synthesizes the mechanistic foundations, preclinical modeling advances, and emerging clinical applications of FUS in PDAC, with emphasis on treatment integration, patient selection, real-time monitoring, and acoustic parameter optimization, while acknowledging current safety considerations and limited clinical toxicity data. Key limitations, translational challenges, and priority knowledge gaps are also discussed to define the role of FUS in multimodal PDAC care.
Insights
Focused ultrasound (FUS) offers a non-invasive approach to treat pancreatic cancer by ablating tumors and improving drug delivery. This technology shows promise for enhancing immunotherapy and other treatments in pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Medical Imaging
- Biotechnology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with poor prognosis due to late detection and treatment resistance.
- The tumor microenvironment in PDAC hinders drug penetration and immune responses, complicating treatment.
- Focused ultrasound (FUS) is an emerging non-invasive technology with potential therapeutic applications in oncology.
Purpose of the Study:
- To review the mechanistic basis, preclinical advancements, and clinical applications of FUS in treating PDAC.
- To explore FUS's potential to overcome PDAC treatment resistance by modulating the tumor microenvironment.
- To discuss the integration of FUS with existing therapies like chemotherapy, radiation, and immunotherapy for PDAC.
Main Methods:
- Review of existing literature on FUS mechanisms and applications in PDAC.
- Synthesis of preclinical data from animal models and early clinical studies.
- Analysis of FUS parameters, safety profiles, and integration strategies for PDAC treatment.
Main Results:
- FUS can induce tumor ablation through thermal and non-thermal effects (cavitation, sonoporation, histotripsy).
- FUS enhances drug and nanoparticle delivery by disrupting stromal barriers and increasing permeability.
- FUS-induced cell death can promote immunogenic responses, supporting combination therapies.
Conclusions:
- FUS presents a promising non-invasive modality for multimodal treatment of PDAC.
- Optimization of acoustic parameters, patient selection, and real-time monitoring are crucial for FUS efficacy and safety.
- Further research is needed to address translational challenges and define FUS's role in improving PDAC patient outcomes.
More Related Videos
06:57Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
